Table 3 Patient-related outcomes at follow-up
| Â | Between group differencea (TAU-IBER) 16-week follow up | Between group differencea (TAU-IBER) 32-week follow up | ||
|---|---|---|---|---|
Mean (95% CI) N | Effect sizeb | Mean (95% CI) | Effect sizeb | |
Generalised Anxiety Disorder Assessment (GAD7) Minimal improvement: 4 points reduction (Loussaint et al. 2020) | 1.4 (− 1.3 to 4.0) N = 44 | 0.16 | 0.2 (− 2.4 to 2.8) N = 44 | 0.02 |
Quick Inventory of Depressive Symptomatology–Self Report (QIDS-SR) Minimal improvement: 28.5% reduction (Masson and Tejani 2013) | 2.8 (0.5 to 5.1) N = 47 | 0.29 | 1.7 (− 1.0 to 4.4) N = 45 | 0.18 |
Altman Self-Rating Scale for Mania (ASRM) Minimal improvement: 5.4 reduction (Altman et al. 2001) | − 0.5 (− 1.6 to 0.6) N = 48 | − 0.18 | − 0.5 (− 2.3 to 1.3) N = 45 | − 0.18 |
EuroQol EQ-5D-5L, index Minimal improvement: 0.05 increase (Payakachat et al. 2015) | − 0.07 (− 0.18 to 0.04) N = 48 | − 0.11 | − 0.002 (− 0.14 to 0.14) N = 48 | − 0.003 |
EuroQol EQ-5D-5L, VAS Minimal improvement: 5 increase (Goranitis et al. 2016) | − 3.5 (− 15.5 to 8.3) N = 48 | − 0.06 | − 2.0 (− 13.3 to 9.3) N = 48 | − 0.03 |
ICEpop CAPability measure for Adults (ICECAP-A) Minimal improvement: 0.3 increase (Goranitis et al. 2016) | −0.12 (− 0.21 to -0.03) N = 48 | − 0.18 | − 0.03 (− 0.13 to 0.06) N = 48 | − 0.04 |
Oxford CAPabilities questionnaire-Mental Health (OxCAP-MH) – 117 Minimal improvement: 6.47 decease (Vergunst et al. 2017) | − 4.8 (− 8.5 to -1.1) N = 47 | − 0.08 | − 3.5 (− 7.4 to 0.4) N = 47 | − 0.07 |